Full Text View
Tabular View
No Study Results Posted
Related Studies
Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer
This study is currently recruiting participants.
Verified by Stanford University, November 2008
First Received: December 4, 2007   Last Updated: November 26, 2008   History of Changes
Sponsored by: Stanford University
Information provided by: Stanford University
ClinicalTrials.gov Identifier: NCT00568360
  Purpose

Endoscopy is a standard part of the evaluation of patients with head and neck cancer used for determining the extent of tumor involvement. However, not all areas involved by tumor are apparent visually. Preliminary results indicate that compared with normal tissues, tumors have abnormal levels of capillary oxygenation. The purpose of this study is to determine the ability of non-pulsatile visible light tissue oxygen monitoring to differentiate normal and tumor tissue based on capillary oxygenation during endoscopy Should this be possible, this method could be used to mark tumor extent and invasion, even when that invasion is up to 5mm blow the tissue surface.


Condition Intervention
Head and Neck Cancer
Device: Oximeter

MedlinePlus related topics: Cancer Endoscopy Head and Neck Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer

Further study details as provided by Stanford University:

Estimated Enrollment: 20
Study Start Date: February 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:All patients with newly diagnosed head and neck cancer as well as those being seen for routine follow up with no evidence of current disease and healthy volunteers are eligible for this study.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568360

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Peter Maxim, MD     650-724-3018     peter.maxim@stanford.edu    
Contact: Cancer Clinical Trials Office     (650) 498-7061        
Principal Investigator: Peter Maxim PhD            
Sub-Investigator: Dr. Billy W. Loo Jr. M.D. Ph.D.            
Sub-Investigator: Quynh-Thu Le            
Sub-Investigator: Dr Ranjiv Sivanandan            
Sub-Investigator: Lei Xing            
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Peter Maxim PhD Stanford University
  More Information

No publications provided

Study ID Numbers: SU-11062007-817, 79938, ENT0014, NCT00568360
Study First Received: December 4, 2007
Last Updated: November 26, 2008
ClinicalTrials.gov Identifier: NCT00568360     History of Changes
Health Authority: United States: Food and Drug Administration;   United States: Institutional Review Board

Study placed in the following topic categories:
Head and Neck Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Head and Neck Neoplasms

ClinicalTrials.gov processed this record on May 06, 2009